Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma

Paolo A. Ascierto*, David Minor, Antoni Ribas, Celeste Lebbe, Anne O'Hagan, Niki Arya, Mary Guckert, Dirk Schadendorf, Richard F. Kefford, Jean Jacques Grob, Omid Hamid, Ravi Amaravadi, Ester Simeone, Tabea Wilhelm, Kevin B. Kim, Georgina V. Long, Anne-Marie Martin, Jolly Mazumdar, Vicki L. Goodman, Uwe Trefzer

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

388   Link opens in a new tab Citations (Scopus)

Fingerprint

Dive into the research topics of 'Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science